Eversana, ArisGlobal team up on drug-safety automation

By Jenni Spinner contact

- Last updated on GMT

(LerinaInk/iStock via Getty Images Plus)
(LerinaInk/iStock via Getty Images Plus)

Related tags: Eversana, Drug development, Pharmacovigilance, Safety, Research and development

The two companies plan to work together on technology that advances pharmacovigilance in order to increase safety and effectiveness of new therapies.

Life-sciences commercialization specialist Eversana is partnering with ArisGlobal, a provider of software designed to automate drug development functions. Together, the two firms plan to work on solutions that improve pharmacovigilance services in a way that increases the safety and effectiveness of new drugs.

Vikram Anand, executive vice president of Eversana’s Compliance Business Unit, said the technology will help streamline regulatory compliance, a frequent source of headaches in the industry.

Compliance is a compulsory part of the pharmaceutical ecosystem, yet it is commonly delivered by disjointed platforms, teams, call centers and data​,” he said. “We’re leading the digital transformation of integrated compliance services, powered by seamless data and services automation, to ultimately create the highest levels of efficacy, effectiveness and safety that only an integrated commercial services provider can deliver​.”

In the collaboration, Eversana plans to harness ArisGlobal’s LifeSphere safety platform for clinical and commercial product safety management, including intelligent automation and machine-learning-enhanced adverse event case processing. The technology is intended to bring real-time predictive intelligence to Eversana’s pharmacovigilance services, such as the ability to process and analyze safety data, identify safety issues and make recommendations for appropriate product utilization that maximizes patient outcomes.

According to the two companies, the strategic partnership will help clients effect critical decisions around product life cycle management, including therapeutic area or geographic expansion, predictive safety for targeted population, off-label use and personalized safety in the era of gene and cell therapy. Eversana reportedly began onboarding clients to the platform, with plans to expand with more than 20 additional clients by mid-2021.

Eversana’s focus on bringing innovation to the commercialization process is perfectly aligned with ArisGlobal’s mission to create the life sciences industry’s smartest R&D software platform​,” said Sankesh Abbhi, president and CEO of ArisGlobal. “We’re proud to expand our partnership with Eversana, which will help bring safer, more effective therapies to market and improve the lives of patients around the world.”

Eversana has entered into a number of strategic and technology partnerships in recent months. In November, the company joined forces with Evoke Pharma on a nasal drug for diabetic gastroparesis​; back in August, they announced a collaboration with ICER on a comprehensive research data assessment​.

Related news

Show more

Related products

show more

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Related suppliers

Follow us

Products

View more

Webinars